logo
Highmark Blue Shield expands virtual care to include pelvic health, joint pain

Highmark Blue Shield expands virtual care to include pelvic health, joint pain

Highmark is continuing its efforts to increase access to health care by offering new ways for members to receive care virtually.
The most recent addition is Virtual Pelvic Health, Bloom by Sword, a program designed to address pelvic health dysfunction, such as bladder issues, chronic pelvic pain and other symptoms. Highmark introduced it in July 2024 and has since seen more than 10,000 members enroll.
'Virtual care is an important part of Highmark's overall Living Health strategy,' said Mari Vandenburgh, vice president of health programs and solutions.
'Highmark believes it's our responsibility to make it easier for members to access the care they need when they need it,' Vandenburgh said. 'As an integrated health system, we are in a unique position to break down barriers to care by offering ease of access and use through our virtual solutions that can complement the care members are receiving in person with their provider of choice.'
A new approach
The Virtual Pelvic Health program is Highmark's second with Sword Health Inc., a New York-based AI health company that specializes in digital health solutions. It is part of Highmark's benefits and available to eligible health plan members at no additional out-of- pocket cost. Participants simply enroll in the program through the My Highmark app or member portal.
Once enrolled, participants are matched with a pelvic health clinician and receive an FDA-listed insertable device and access to a mobile app. A personalized set of pelvic floor exercises are recommended, and the sensor and app work together to monitor the force, endurance and accuracy of the pelvic floor muscles during the exercises.
'That real-time feedback helps participants maximize their results,' Vandenburgh said.
'The Virtual Pelvic Health program provides convenient, on-demand access to pelvic floor care that is focused on both strengthening and relaxation,' she said. 'The combination of the sensor and the feedback that a user receives in the app really helps to monitor progress in their program. The app also provides educational resources to individuals that help to support behavior change and habit formation in the population of individuals that could benefit from pelvic floor support.'
Participants have reported significant improvements in their quality of life, including a reduction in symptoms they previously experienced. Additionally, the program has helped alleviate the stigma often associated with pelvic floor conditions, improving mental health.
Virtual joint health
The Virtual Pelvic Health program follows Highmark's introduction of Virtual Joint Health, Thrive by Sword to self-funded plans in 2022. In that program, a licensed physical therapist assigns a series of exercises for people looking to alleviate musculoskeletal pain based on their specific goals.
Participants then receive a tablet they can use at home as they complete the exercises. The tablet is equipped with advanced motion sensing technology to provide real-time feedback and ensure people use proper form. It also shares data with their physical care specialist to monitor progress and, if necessary, adjust their recommended exercise plan to better accommodate their needs.
'It really enables members to address their joint health needs at the time that's most convenient for them,' Vandenburgh said. 'They can do the exercises in the comfort of their own home, and it reduces the barriers of time and access to care if there are delays in getting appointments.'
In 2024, the insurer expanded it to fully insured plans. So far, more than 36,000 Highmark members have enrolled in the program.
The feedback has been positive, Vandenburgh said, with 88% of participants describing it as easy to use and 72% completing the program.
Health outcomes also have been strong, with 69% of participants reporting a significant improvement in their joint pain and 35% reduction in the intent to pursue surgery to address their pain.
'Another positive outcome that users report is that 26% say they saw an improvement in their work and productivity impairment,' she said. 'We're also monitoring the behavioral health impacts of joint health and increasing screenings for depression and anxiety.'
Expanded reach
Highmark's virtual care offerings include a virtual triage tool, virtual primary care, a virtual urgent care clinic and virtual specialty care clinics for behavioral health, women's health and dermatology, as well as a digital diabetes management solution.
Offering on-demand, virtual care helps people get the care they need to improve their health while lowering costs, Vandenburgh said. The Virtual Joint Health program, for example, has reduced costs by $112 per member per month in comparison to a control group. That savings can then be reinvested back into delivering a remarkable health experience, so it's easier for members to engage and manage their health.
'Virtual Joint Health and Virtual Pelvic Health deliver a win-win combination by boosting employer productivity and lowering cost, while simultaneously enabling employees convenient access to care and improved quality of life,' she said. 'We see continued growth in engagement and enrollment in our digital solutions and programs year over year.'
To learn more visit highmark.com/employer.
Lauren Lawley Head is a freelance writer.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Unlocking Cellular Health With Science and Trust
Unlocking Cellular Health With Science and Trust

Los Angeles Times

time2 hours ago

  • Los Angeles Times

Unlocking Cellular Health With Science and Trust

In the longevity and wellness space, Niagen Bioscience is charting a course defined by both scientific rigor and an unwavering commitment to responsible innovation Niagen Bioscience (NASDAQ: NAGE, formerly Chromadex) is a Los Angeles-based company dedicated to advancing the supplements industry using science-backed research into their component ingredients. At the helm is CEO Robert Fried, who says the company's mission is to pioneer NAD+ research and develop transformative NAD-boosting healthy-aging solutions with Niagen, their patented form of nicotinamide riboside (NR). Niagen is the cornerstone of the company's clinically proven product portfolio, Tru Niagen and Niagen IV and injections. During this year's Cannes Lions, Fried sat down with LA Times Studios to discuss how the company is pioneering the NAD+ space and the science and quality backed benefits of its Niagen products. 'NAD+, or nicotinamide adenine dinucleotide, is a co-enzyme found in all living cells – plant and animal – and is involved in all important metabolic processes within the cell, but especially energy metabolism and DNA repair, which are key to supporting mitochondrial health and overall optimal health.' explained Fried. Mitochondria, the 'battery pack of the cell,' combines nutrients from the food you eat and oxygen with NAD+ to produce energy. NAD+ also plays a crucial role in DNA recovery and cellular repair. 'All of these processes that exist within the cell where the cell repairs damage are NAD+ dependent,' Fried emphasized, illustrating how higher NAD+ levels facilitate rapid healing, contrasting youthful recovery with a slower healing process that occurs as we age. This is because NAD+ starts to decline naturally in our 30s, with research showing a dramatic drop of up to 65% by the time we reach age 70. Exposure to stressors like sedentary lifestyle, excess sun exposure, poor diet and environmental factors also impact NAD+ levels. Research shows that NAD+ decline is associated with a decline in overall health and vitality, contributing to the development of conditions and disease. Fried is quick to address a significant industry misconception: 'NAD+ itself is not bioavailable. If you consume NAD+ orally or with an IV, it will not elevate NAD+ levels inside your cells.' He clarified that the NAD+ molecule is too large to penetrate cells, causing NAD+ supplements and IV to be ineffective. Intact NAD+ may even have the potential to cause acute immune inflammatory response, which may be responsible for the uncomfortable side effects associated with NAD+ IV and injections. The solution, according to Fried, is 'to consume an NAD+ precursor molecule that easily gets into the cell and then converts into NAD+, and the best molecule for this is called nicotinamide riboside or NR.' Niagen is patented NR and precisely what Tru Niagen and pharmaceutical-grade Niagen IV and injections offer. With a legacy spanning over 25 years, the company's recent rebranding from ChromaDex to Niagen Bioscience reflects its sharpened focus. 'We're no longer only a reference standards company but an NAD+ company dedicated to addressing one of life's most complex challenges - aging,' said Fried. Niagen Bioscience differentiates itself by operating as an 'R&D lab that specializes in NAD+,' not simply a supplement distributor, he said. Its distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and an external research program helping independent investigators and institutions worldwide uncover the potential of NAD+. 'There is no other company in the supplement space that comes close this level of R&D investment and scientific research,' Fried asserted. The company boasts 38 peer-reviewed, published human clinical studies on oral food-grade Niagen, of which about 95% are completely independent, with another 40 studies currently underway. This level of scientific rigor, he contends, is typically found only in biotech or pharmaceutical companies. Products are tested at the manufacturing facility and then retested upon delivery. Fried notes their marketing: 'We are real. We are genuine. We let the science do the talking.' This approach, he believes, is key to building genuine trust. Niagen Bioscience is exploring Niagen's broader therapeutic potential for its patented NR. Fried reveals extensive clinical studies on the benefits of its patented food-grade NR for specific age-related and orphan diseases (rare conditions characterized by rapid aging). Some of these studies have reached Phase II and III clinical trials. A 52 week, 400-participant, Phase III double-blinded, controlled study on Parkinson's disease recently concluded, conducted with a world-renowned independent researcher. 'That is a level of scientific research ... that you don't see from supplement companies,' Fried emphasized. Niagen Bioscience is also innovating beyond oral supplements. They've developed a pharmaceutical-grade version of nicotinamide riboside, now available as Niagen IV. exclusively at clinics across the U.S. Fried highlighted its advantages: 'If you do an injection or an IV, you're getting the benefits of Niagen directly to the bloodstream.' This results in faster absorption and avoids side effects often associated with direct NAD+ infusions. Fried candidly addresses his concern about a lack of public trust in the dietary supplement industry, citing prevalent unsubstantiated claims, low-quality products, and marketing hype. 'It's my belief that if people genuinely trusted the companies that the industry at large would be so significant because we'd actually have preventative health value,' he states. To combat this, Niagen Bioscience has proposed a 'Trust Alliance' – a coalition of industry players, government and non-profits to test products and ensure claims are met. For Fried, the most meaningful aspect of his journey is receiving letters from individuals who experienced health benefits after taking Tru Niagen. Looking ahead, Niagen Bioscience aims to solidify its position as the 'gold standard in the NAD+ space,' continuing its scientific leadership. 'Our mission is to help every living being around the world age better. We think what could happen in the next five years is very exciting and special,' Fried concluded.

Radiopharm Theranostics Limited (RADX) Receives IND Approval From FDA To Initiate Phase I Therapeutic Clinical Study To Target B7H3 With Betabart (RV-01)
Radiopharm Theranostics Limited (RADX) Receives IND Approval From FDA To Initiate Phase I Therapeutic Clinical Study To Target B7H3 With Betabart (RV-01)

Yahoo

time4 hours ago

  • Yahoo

Radiopharm Theranostics Limited (RADX) Receives IND Approval From FDA To Initiate Phase I Therapeutic Clinical Study To Target B7H3 With Betabart (RV-01)

Radiopharm Theranostics Limited (NASDAQ:RADX) is among the 12 Best Australian Stocks to Buy Right Now. The company recently announced receiving Investigational New Drug (IND) approval from the FDA to begin a Phase 1 therapeutic clinical study to target B7H3 with Betabart (RV-01). A well-stocked pharmacy shelf full of the company's pharmaceuticals, nutraceuticals, over-the-counter medications, and health care products. The Lu-177-B7H3 monoclonal antibody is the first in class targeted radiopharmaceutical that is being developed against the 4lg type of B7H3. Radiopharm Theranostics Limited (NASDAQ:RADX) believes it has the potential to become a highly differentiated drug for treating individuals with aggressive solid tumors. The company says it is on track to initiate the first-in-human study during the fourth quarter of this calendar year. Findings from recent preclinical studies have shown that RV-01 exhibits hepatic clearance, which allows the isotope enough time to target tumors, while also potentially reducing adverse effects such as hematological toxicities. Moreover, these monoclonal antibodies are cleared by the liver, unlike peptides and small molecules. This, coupled with the shortened half-life of RV-01, makes this agent stand out compared to other monoclonal antibodies and targeted radiotherapeutics with a renal excretion pathway. Radiopharm Theranostics Limited (NASDAQ:RADX) is an Australia-based clinical-stage radiotherapeutics firm developing innovative radiopharmaceutical products for therapeutic and diagnostic applications in areas of high unmet medical need. While we acknowledge the potential of RADX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Best Large Cap Defense Stocks to Buy According to Analysts and 10 Best Low Priced Defense Stocks to Buy Now. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Incannex Healthcare Inc. (IXHL) Receives Positive Patient-Reported Outcomes For IHL-42X in Obstructive Sleep Apnoea
Incannex Healthcare Inc. (IXHL) Receives Positive Patient-Reported Outcomes For IHL-42X in Obstructive Sleep Apnoea

Yahoo

time4 hours ago

  • Yahoo

Incannex Healthcare Inc. (IXHL) Receives Positive Patient-Reported Outcomes For IHL-42X in Obstructive Sleep Apnoea

Incannex Healthcare Inc. (NASDAQ:IXHL) is among the 12 Best Australian Stocks to Buy Right Now. On August 8, the company announced positive new patient-reported outcomes from participants in its RePOSA Phase 2 trial of IHL-42X to treat obstructive sleep apnoea (OSA). A scientist in a lab coat examining a Petri dish containing a biopharmaceutical culture. The new insights were collected through exit interviews, in line with FDA's guidance on Patient-Focused Drug Development (PFDD). The results build on already compelling data to reinforce the potential of IHL-42X to improve sleep quality, cognitive function, and daily life. Incannex Healthcare Inc. (NASDAQ:IXHL) said that 57.6% of the respondents reported an improvement in their OSA, of which 89.5% described it as a meaningful change to their lives. Some of the reported benefits include better sleep quality, reduced sleepiness during the daytime, feeling fresh in the morning, and other cognitive and daily-life improvements. Joel Latham, President and CEO of Incannex Healthcare Inc. (NASDAQ:IXHL) stated the following on the findings: 'Our recent Phase 2 results for IHL-42X exceeded expectations. In some patients, we observed reductions in AHI of up to 83%, which is an extraordinary outcome and a powerful signal of the drug's potential. We believe the findings from the patient exit interviews underscore that these improvements are not just clinical—they are translating into meaningful, positive changes in patients' daily lives. This reinforces our belief that IHL-42X has the potential to significantly shift the treatment paradigm for OSA.' Incannex Healthcare Inc. (NASDAQ:IXHL) is a clinical-stage pharmaceutical company developing medicines to treat chronic conditions, including obstructive sleep apnea, generalized anxiety disorder, and rheumatoid arthritis. While we acknowledge the potential of IXHL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Best Large Cap Defense Stocks to Buy According to Analysts and 10 Best Low Priced Defense Stocks to Buy Now. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store